Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Natera Inc. Common Stock (NTRA) vs TJX Companies Inc (TJX) Price & Performance

Natera Inc. Common StockTrade
TJX Companies IncTrade

Price performance (Past 24H)

Key statistics

Natera Inc. Common Stock vs TJX Companies Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while TJX Companies Inc trades at $143.3 (market cap $155.64B). The key difference: TJX Companies Inc is far larger — about 2.7× Natera Inc. Common Stock's market cap, and TJX Companies Inc pays a 1.36% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and TJX Companies Inc for 97 Days on average.

NTRATJX
Market Cap
$57.03B$155.64B
Volume
1,131,1577,499,607
Sector
HealthConsumer Cyclical
52-Week High
$425.64$168.41
52-Week Low
$179.42$122.84
Typical Hold Time
0 Days97 Days
Enterprise Value
$56.18B$163.95B
Dividend Yield
—1.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Natera Inc. Common Stock

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

TJX Companies Inc

TJX trades at $142.80, up 0.62% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $56.36B in 2025, with net income of $4.86B and a high ROE of 62.17%. The stock is near its pivot point of $141, with resistance at $143 and support at $139. Analysts are overwhelmingly positive, with an 84.9% buy rating and a consensus price target of $174.15.

Outlook remains positive due to consistent earnings outperformance and projected revenue growth to $62.4B in 2026. Risks include high valuation multiples (P/E 26.2) and competitive pressures in off-price retail. Upside potential is supported by Wall Street optimism and strong cash flow trends.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NTRA
100% Buy0% Sell
Avg holding period · 0 Days
TJX
37% Buy63% Sell
Avg holding period · 97 Days

Top news

Latest headlines on both assets

About Natera Inc. Common Stock

Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.

Read more on NTRA →

About TJX Companies Inc

TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.

Read more on TJX →